PBPK


Also found in: Medical.
AcronymDefinition
PBPKPhysiologically Based Pharmacokinetic Modeling
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
4: Enabling technologies for investigative toxicology: AI, artificial intelligence; AOP, adverse outcome pathway; GCCP, Good Cell Culture Practice; HTS, high-throughput screening; IATA, integrated approaches to testing and assessment; ITS, integrated testing strategy; MoA, mode of action; MPS, microphysiological systems; PBPK, physiology-based pharmacokinetic modeling; PoT, pathways of toxicity; (Q)SAR, (quantitative) structure activity relationships
Here, we shift the focus of PET kinetic modelling from the study of an individual process or organ to in vivo whole-body PBPK modelling in mice.
Under the new agreement, FDA has almost tripled its number of licenses, equipping its modeling and simulation (M and S )review team with almost 60 PBPK licenses.
Dichloromethane's External Peer Review "Agree:Disagree" Table Question Answer Ratio Key Terms (Agree:Disagree) A1a 5:2 Reviewer 1: Agree -agree with the PBPK model used for internal dosimetry Reviewer 2: Agree -agree with the PBPK model used for internal dosimetry Reviewer 3: Agree -agree with the PBPK model used for internal dosimetry Reviewer 4: Disagree -disagree with the PBPK model used for internal dosimetry Reviewer 5: Disagree -disagree with the PBPK model used for internal dosimetry Reviewer 6: Agree -agree with the PBPK model used for internal dosimetry Reviewer 7: Agree -agree with the PBPK model used for internal dosimetry Table V.
Mechanistic physiologically-based pharmacokinetic (PBPK) models, such as the Simcyp Simulator, can be used to estimate in vivo dissolution rather than just the systemic input rate, separately accounting for permeation, GI transit and first-pass elimination.
PBPK models have become a staple for chemical risk assessments by the US EPA (Environmental Protection Agency) and the WHO International Program on Chemical Safety (IPCS).
Human PK prediction takes into consideration bioavailability of a drug candidate, allometric scaling and physiologically-based PK (PBPK) modeling.
The company has four business units Certara Strategic Consulting, Certara Software, Simcyp (which focuses on PBPK), and Synchrogenix (which specialises in regulatory writing).
This would enable improvements in in vivo extrapolation and PBPK modelling.
The 11 contributions describe physiologically based pharmacokinetic (PBPK) models for simulating dose metrics in sensitive subpopulations, a dynamic systems model of rat liver homeostasis, the quantitative structure-activity relationship (QSAR) tool for simulating necessary endpoints, and omics biomarker discovery.
In a pilot study funded by the American Chemistry Council Long-Range Research Initiative (see (5.10) in Table 5), the TNO team applied PBPK models to assess possible toxicokinetic interactions between compounds in an applied mixture and compared those estimates to empirical dose-response modeling of observed pathological changes in the liver, blood, and kidney.